Editor’s Choice: Experimental Trial for ALS and New Insights on COVID-19

Happy Friday!

We’re about halfway through Stevens-Johnson Syndrome Awareness Month. It’s a type of severe skin reaction that often involves admission to a burn unit for treatment. Looking for ways to help out? This is a good place to start. We also have information about a clinical trial that is moving forward for an experimental treatment for ALS. We also have details on how scientists are exploring the links between COVID-19, chronic fatigue syndrome and Gullain-Barre syndrome. Finally, the latest episode of our podcast, “Wait, How Do You Spell That?” is out! In it, we discuss disease advocacy and service dogs with Amy Dahm, the head of the Cushing’s Support and Research Foundation patient support group for Washington D.C., Maryland and Virginia. Check it out below.  We hope you enjoy your weekend!

 

Clinical Trial Proceeds for Experimental ALS Treatment

Researchers hope that the upcoming study will show the same success as pre-clinical trials, which showed that prevention of degeneration of motor neurons, improved motor function, and prolonged survival.

 

How COVID-19, Chronic Fatigue Syndrome, and Guillain-Barre Syndrome are Linked

The similarities are likely due to the inflammatory effects of the immune response as the body tries to fight off the disease.

 

New Podcast Episode: Wait, How Do You Spell That?

Cushing’s Syndrome and Service Dogs: Discussing Disease Advocacy With Amy Dahm

 


Do you have a rare disease experience of your own? Share with us here.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email